Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.52 |
| ▸ | SUCNR1 | Q9BXA5 | 5/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 5/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 4/20 | 0.32 |
| ▸ | LATS1 | O95835 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.31 |
| ▸ | SKP1 | P63208 | 1/20 | 0.31 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177401 | 0.85 | ATR (0.53) | ATRSUCNR1 | |
| SCHEMBL13138246 | 0.84 | ATR (0.73) | ATR | |
| SCHEMBL16420669 | 0.75 | ATR (0.56) | ATRCYP3A4 | |
| SCHEMBL16489045 | 0.70 | ATR (0.42) | ATRSCN10ASCN2A | |
| SCHEMBL18181011 | 0.70 | ATR (0.74) | ATR | |
| SCHEMBL18177396 | 0.67 | ATR (0.55) | ATRSCN10ASCN2ADYRK1ACYP3A4 | |
| SCHEMBL19102154 | 0.67 | ATR (0.35) | ATR | |
| SCHEMBL16424877 | 0.67 | ATR (0.76) | ATR | |
| SCHEMBL18177393 | 0.65 | SCN2A (0.34) | ATRSCN10ASCN2ADYRK1ACYP3A4 | |
| SCHEMBL16489041 | 0.64 | ATR (0.34) | ATRSCN10ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701674-B2 | Substituted pyrazines as ATR kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2015-02-19 | — | — | US | disclosed |
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PIRAMAL IMAGING SA (CH) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150030539-A1 | COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS | PMP22, MEN1, VHL | ATR 2406/4885SUCNR1 913/4885SCN10A 1832/4885 |
| US-20150051187-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | ATR, CHEK1, MAP3K5 | ATR 1/4885SUCNR1 4326/4885SCN10A 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.